A total of 104 patients were enrolled in a phase 1b, multicenter, open-label trial of lenvatinib (TKIs) plus pembrolizumab (anti-PD-1) in patients with unresectable HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.